A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.

导出原文传递

翻译打印收藏纠错

作者： Lee JL ^[1] ; Kang YK ; Kang HJ ; Lee KH ; Zang DY ; Ryoo BY ; Kim JG ; Park SR ; Kang WK ; Shin DB ; Ryu MH ; Chang HM ; Kim TW ; Baek JH ; Min YJ

作者单位： Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea. ^[1]

关键词 Adenocarcinoma Aged 80 and over Antimetabolites Antineoplastic 腺癌老年人 80以上抗代谢药抗肿瘤骨肿瘤脱氧胞苷复方合剂

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The British journal of cancer

2008年99卷4期

584-590页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

检索历史清除